|
gptkbp:instanceOf
|
halogenated hydrocarbon
inhalational anesthetic
|
|
gptkbp:appearance
|
colorless liquid
|
|
gptkbp:aroma
|
gptkb:sugar
|
|
gptkbp:ATCCode
|
N01AB01
|
|
gptkbp:blood/gas_partition_coefficient
|
2.4
|
|
gptkbp:boilingPoint
|
50.2 °C
|
|
gptkbp:CASNumber
|
151-67-7
|
|
gptkbp:chemicalFormula
|
C2HBrClF3
|
|
gptkbp:color
|
colorless
|
|
gptkbp:contraindication
|
malignant hyperthermia susceptibility
history of halothane hepatitis
|
|
gptkbp:density
|
1.872 g/cm³
|
|
gptkbp:discoveredBy
|
gptkb:Charles_Suckling
|
|
gptkbp:excretion
|
lungs
|
|
gptkbp:firstSynthesized
|
1951
|
|
gptkbp:flammability
|
nonflammable
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Halothane
|
|
gptkbp:introduced_in_medicine
|
1956
|
|
gptkbp:IUPACName
|
2-bromo-2-chloro-1,1,1-trifluoroethane
|
|
gptkbp:KEGGID
|
gptkb:D00125
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:MAC_(minimum_alveolar_concentration)
|
0.75% (adults)
|
|
gptkbp:mechanismOfAction
|
potentiates GABA-A receptor activity
inhibits NMDA receptor
|
|
gptkbp:meltingPoint
|
-44 °C
|
|
gptkbp:MeSH_ID
|
D006214
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:molecularWeight
|
197.38 g/mol
|
|
gptkbp:odor_threshold
|
detectable at low concentrations
|
|
gptkbp:origin
|
gptkb:United_Kingdom
|
|
gptkbp:pregnancyCategory
|
C (US)
|
|
gptkbp:PubChem_CID
|
3562
CHEMBL1200697
DB01159
|
|
gptkbp:replacedBy
|
gptkb:isoflurane
sevoflurane
|
|
gptkbp:routeOfAdministration
|
inhalation
|
|
gptkbp:sideEffect
|
gptkb:arrhythmia
malignant hyperthermia
hepatotoxicity
hypotension
respiratory depression
|
|
gptkbp:solubility
|
slightly soluble
|
|
gptkbp:stabilized_with
|
thymol
|
|
gptkbp:stable
|
decomposes in light
|
|
gptkbp:UNII
|
UQT9G45D1P
|
|
gptkbp:used_in_veterinary_medicine
|
yes
|
|
gptkbp:usedFor
|
general anesthesia
|
|
gptkbp:Vapor_pressure_(at_20°C)
|
243 mmHg
|
|
gptkbp:WHOModelListOfEssentialMedicines
|
yes
|
|
gptkbp:bfsParent
|
gptkb:Anesthetic
|
|
gptkbp:bfsLayer
|
7
|